Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 13, 2025 • 4:00 AM ET

Date/Time Source News Release
05/27/2025 07:00 AM EDT GlobeNewswire Algernon Announces $1M Private Placement
05/22/2025 08:50 PM EDT GlobeNewswire Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition
05/13/2025 07:00 AM EDT GlobeNewswire Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
05/05/2025 07:47 AM EDT GlobeNewswire Algernon Announces Warrant Extension
04/08/2025 07:00 AM EDT GlobeNewswire Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
03/06/2025 07:00 AM EST GlobeNewswire Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
02/11/2025 07:00 AM EST GlobeNewswire Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
02/05/2025 07:00 AM EST GlobeNewswire Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare's USD $170K Equity Investment
01/06/2025 07:00 AM EST GlobeNewswire Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent
11/04/2024 06:30 PM EST GlobeNewswire Algernon Announces Warrant Extension
Page

Additional News

As of June 13, 2025 • 4:00 AM ET

Date/Time Source News Release
03/28/2024 08:40 AM EDT News Direct Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment
03/27/2024 05:08 PM EDT BTV Bulletin Algernon Pharmaceuticals: Next Phase Study of Ifenprodil for COVID-19
03/27/2024 05:08 PM EDT BTV Bulletin News Alert: Algernon Pharmaceuticals: Trial Complete for COVID-19 Treatment
03/27/2024 05:08 PM EDT BTV Bulletin CEO Clips - Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial
03/27/2024 05:08 PM EDT BTV Bulletin Algernon Pharmaceuticals: Investigating a Novel Therapy for Stroke Patients Using the Psychedelic Drug N,N-Dimethyltryptamine (DMT)
12/27/2023 07:50 AM EST SeekingAlpha Algernon Pharmaceuticals increases size of private placement
11/22/2023 07:35 AM EST SeekingAlpha Seyltx acquires Algernon's Chronic Cough Research Program for $2M and 20% stake
11/08/2023 07:18 AM EST SeekingAlpha Algernon gets Japanese patent notice of allowance for treatment of NASH with Repirinast
06/05/2023 01:43 PM EDT News Direct Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study
05/31/2023 01:54 PM EDT News Direct Algernon gets notice of allowance for patent to treat chronic kidney disease in Japan
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.